Urmăriți
Norio Ohmagari, MD, MSc, Ph.D.
Norio Ohmagari, MD, MSc, Ph.D.
Director, Disease Control and Prevention Center National Center for Global Health and Medicine
Adresă de e-mail confirmată pe hosp.ncgm.go.jp - Pagina de pornire
Titlu
Citat de
Citat de
Anul
Remdesivir for the treatment of Covid-19
JH Beigel, KM Tomashek, LE Dodd, AK Mehta, BS Zingman, AC Kalil, ...
New England Journal of Medicine 383 (19), 1813-1826, 2020
58872020
Compassionate use of remdesivir for patients with severe Covid-19
J Grein, N Ohmagari, D Shin, G Diaz, E Asperges, A Castagna, T Feldt, ...
New England Journal of Medicine 382 (24), 2327-2336, 2020
32172020
Remdesivir for the treatment of Covid-19—preliminary report
JH Beigel, KM Tomashek, LE Dodd, AK Mehta, BS Zingman, AC Kalil, ...
New England Journal of Medicine 383 (19), 1813-1836, 2020
25322020
Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells
S Matsuyama, N Nao, K Shirato, M Kawase, S Saito, I Takayama, ...
Proceedings of the National Academy of Sciences 117 (13), 7001-7003, 2020
14082020
Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development
M Imai, K Iwatsuki-Horimoto, M Hatta, S Loeber, PJ Halfmann, ...
Proceedings of the National Academy of Sciences 117 (28), 16587-16595, 2020
9862020
Efficacy of antibodies and antiviral drugs against Covid-19 Omicron variant
E Takashita, N Kinoshita, S Yamayoshi, Y Sakai-Tagawa, S Fujisaki, M Ito, ...
New England Journal of Medicine 386 (10), 995-998, 2022
3552022
ACTT-1 Study Group Members
JH Beigel, KM Tomashek, LE Dodd, AK Mehta, BS Zingman, AC Kalil, ...
Remdesivir for the treatment of Covid-19—final report. N Engl J Med 383 (19 …, 2020
3012020
Efficacy of antiviral agents against the SARS-CoV-2 omicron subvariant BA. 2
E Takashita, N Kinoshita, S Yamayoshi, Y Sakai-Tagawa, S Fujisaki, M Ito, ...
New England Journal of Medicine 386 (15), 1475-1477, 2022
2792022
The anticoagulant nafamostat potently inhibits SARS-CoV-2 S protein-mediated fusion in a cell fusion assay system and viral infection in vitro in a cell-type-dependent manner
M Yamamoto, M Kiso, Y Sakai-Tagawa, K Iwatsuki-Horimoto, M Imai, ...
Viruses 12 (6), 629, 2020
2442020
Multilocus sequence typing (MLST) for characterization of Enterobacter cloacae
T Miyoshi-Akiyama, K Hayakawa, N Ohmagari, M Shimojima, T Kirikae
PloS one 8 (6), e66358, 2013
2312013
Two cases of Zika fever imported from French Polynesia to Japan, December 2013 to January 2014
S Kutsuna, Y Kato, T Takasaki, ML Moi, A Kotaki, H Uemura, T Matono, ...
Eurosurveillance 19 (4), 2014
2252014
Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug …
K Matsumoto, Y Takesue, N Ohmagari, T Mochizuki, H Mikamo, M Seki, ...
Journal of Infection and Chemotherapy 19, 365-380, 2013
2222013
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA. 2
R Uraki, M Kiso, S Iida, M Imai, E Takashita, M Kuroda, PJ Halfmann, ...
Nature 607 (7917), 119-127, 2022
2132022
Clinical epidemiology of hospitalized patients with coronavirus disease 2019 (COVID-19) in Japan: report of the COVID-19 registry Japan
N Matsunaga, K Hayakawa, M Terada, H Ohtsu, Y Asai, S Tsuzuki, ...
Clinical Infectious Diseases 73 (11), e3677-e3689, 2021
2112021
First and second COVID-19 waves in Japan: a comparison of disease severity and characteristics
S Saito, Y Asai, N Matsunaga, K Hayakawa, M Terada, H Ohtsu, ...
The Journal of infection 82 (4), 84, 2021
2072021
Novel SARS-CoV-2 variant in travelers from Brazil to Japan
T Fujino, H Nomoto, S Kutsuna, M Ujiie, T Suzuki, R Sato, T Fujimoto, ...
Emerging infectious diseases 27 (4), 1243, 2021
2062021
Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo …
H Montgomery, FDR Hobbs, F Padilla, D Arbetter, A Templeton, ...
The Lancet Respiratory Medicine 10 (10), 985-996, 2022
2042022
Autochthonous dengue fever, tokyo, japan, 2014
S Kutsuna, Y Kato, ML Moi, A Kotaki, M Ota, K Shinohara, T Kobayashi, ...
Emerging infectious diseases 21 (3), 517, 2015
2002015
Prolonged and late-onset symptoms of coronavirus disease 2019
Y Miyazato, S Morioka, S Tsuzuki, M Akashi, Y Osanai, K Tanaka, ...
Open forum infectious diseases 7 (11), ofaa507, 2020
1482020
Analysis of the clinical pipeline of treatments for drug-resistant bacterial infections: despite progress, more action is needed
MS Butler, V Gigante, H Sati, S Paulin, L Al-Sulaiman, JH Rex, ...
Antimicrobial agents and chemotherapy 66 (3), e01991-21, 2022
1352022
Sistemul nu poate realiza operația în acest moment. Încercați din nou mai târziu.
Articole 1–20